心源性休克的流行病学、病理生理与当代管理:欧洲心脏病学会心力衰竭协会立场声明
该立场声明由欧洲心脏病学会心力衰竭协会制定,总结心源性休克的定义、流行病学、病因、病理生理与管理。心源性休克从初始打击进展为器官衰竭和死亡,表现谱广,取决于急性心脏打击与患者基础心脏及整体状况的交互。表型分型可能影响管理,因分类可支持启动适当治疗。管理需考虑医疗服务组织,及时对适当选择的患者给予治疗并避免医源性伤害。尽管已有若干共识驱动的算法,管理仍具挑战,多数受试疗法未获疗效与安全性证据,结局仍差。
要点
- 心源性休克是连续性综合征,从初始打击进展至器官衰竭和死亡,死亡率极高。
- 心源性休克表现谱广,取决于急性心脏打击与患者基础心脏及整体状况的交互。
- 表型分型可能对管理有临床影响,因分类可支持启动适当治疗。
- 管理需考虑医疗服务组织,及时对适当选择的患者给予治疗,同时避免医源性伤害。
- 多数受试疗法未获疗效与安全性证据,结局仍差,未来研究应识别新病理生理靶点。
适用人群与场景
- 心源性休克患者,表现谱取决于急性心脏打击与患者基础心脏及整体医疗状况的交互。
处置流程与药物剂量
- 心源性休克管理应考虑医疗服务组织的适当安排。
- 治疗必须及时给予适当选择的患者,同时避免医源性伤害。
研究设计与关键结果
- 该文为欧洲心脏病学会心力衰竭协会立场声明,总结心源性休克定义、流行病学、病因、病理生理与管理的当前知识,重点改善院内管理。
- 心源性休克从初始打击进展至器官衰竭和死亡,死亡率极高。
- 若干共识驱动的算法已被提出,但管理仍具挑战,多数受试疗法未获疗效与安全性证据,结局仍差。
证据类型、等级与局限
- 证据类型:欧洲心脏病学会心力衰竭协会立场声明。
- 局限:原文未报告局限性。
对床旁实践的改变
- 表型分型可能对管理有临床影响,因分类可支持启动适当治疗。
- 治疗须及时给予适当选择的患者,同时避免医源性伤害;作者认为未来研究应识别新病理生理靶点,高质量转化研究应促进将更有针对性的干预纳入临床研究方案以改善个体患者结局。
指南或共识出处
- 欧洲心脏病学会心力衰竭协会立场声明:心源性休克的流行病学、病理生理与当代管理。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Cardiogenic shock (CS) is a complex multifactorial clinical syndrome with extremely high mortality, developing as a continuum, and progressing from the initial insult (underlying cause) to the subsequent occurrence of organ failure and death. There is a large spectrum of CS presentations resulting from the interaction between an acute cardiac insult and a patient's underlying cardiac and overall medical condition. Phenotyping patients with CS may have clinical impact on management because classification would support initiation of appropriate therapies. CS management should consider appropriate organization of the health care services, and therapies must be given to the appropriately selected patients, in a timely manner, whilst avoiding iatrogenic harm. Although several consensus-driven algorithms have been proposed, CS management remains challenging and substantial investments in research and development have not yielded proof of efficacy and safety for most of the therapies tested, and outcome in this condition remains poor. Future studies should consider the identification of the new pathophysiological targets, and high-quality translational research should facilitate incorporation of more targeted interventions in clinical research protocols, aimed to improve individual patient outcomes. Designing outcome clinical trials in CS remains particularly challenging in this critical and very costly scenario in cardiology, but information from these trials is imperiously needed to better inform the guidelines and clinical practice. The goal of this review is to summarize the current knowledge concerning the definition, epidemiology, underlying causes, pathophysiology and management of CS based on important lessons from clinical trials and registries, with a focus on improving in-hospital management.
参考来源
- Chioncel O, Parissis J, Mebazaa A, et al. Epidemiology, pathophysiology and contemporary management of cardiogenic shock - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020. PMID: 32469155. doi:10.1002/ejhf.1922
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。